Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Michael Amoroso has been named CEO of Abeona Therapeutics. Formerly, Amoroso was the senior vice president and chief commercial officer at Kite Pharma.
Alligator Bioscience has brought on Søren Bregenholt as the company’s newest CEO. Bregenholt comes from Macrophage Pharma, where he also served as CEO.
Diana Brainard, former vice president at Gilead Sciences, has been named CEO of AlloVir. Brainard also had been serving as senior vice president and head of the virology therapeutic area at Gilead Sciences.
Antengene has appointed Kevin Lynch as its new chief medical officer. Lynch formerly was Celgene’s vice president and head of clinical development and medical affairs. Joining him in a new role as chief scientific officer is Bo Shan, previously Antengene’s corporate vice president.
Robert Willette has been named chief scientific officer of APIE Therapeutics. Most recently, Willette was interim chief science officer at Complexa Therapeutics.
Alexandre Kaoukhov has been named senior vice president and head of clinical development of Bioniz Therapeutics. Kaoukhov was most recently head of global development at Almirall.
Calyx has appointed Stephen Bravo to the role of chief medical officer. Formerly, Bravo was managing partner and medical director at Sand Lake Imaging.
Eledon Pharmaceuticals has tapped Jeff Bornstein for the role of chief medical officer. Bornstein was most recently the vice president and head of clinical sciences, gastroenterology at Takeda Pharmaceuticals.
Kim Arvid Nielsen has been named Follicums’ new CEO. Nielsen’s background includes stints at Cytovac, Scandion Oncology, Serendex, Bayer, Pharmion, Ferrosan and Serono Nordic. Previous CEO Jan Alenfall will temporarily take the newly created position of chief scientific officer.
Judith Dunn has been named president of R&D at Fulcrum Therapeutics. Dunn jumps over to Fulcrum from Atlas Venture, where she served as an Entrepreneur in Residence.
Bart Filius has added the title of president to his current title of chief operating officer at Galapagos. Prior to joining Galapagos, Filius was vice president and chief financial officer of the European division at Sanofi.
Sven Zimmermann, former chief financial officer at MetrioPharm, has been named CEO of Inotrem.
Alan Jacobs has been named chief medical officer of Minovia Therapeutics. Prior to joining Minovia, Jacobs was chief medical officer for Aspire Health Science.
Anthony Caggiano, former chief medical officer of Cognition Therapeutics, has been named chief medical officer of NeuroTrauma Sciences.
Peter Braun has been appointed CEO of Nordic Nanovector. Prior to joining Nordic, Braun was chief commercial officer for Biofourmis.
Jonathan Mayhew has been named CEO of Ontrak. Mayhew most recently served as executive vice president and chief transformation officer for CVS Health.
Founder of Paragonix Technologies, Lisa Anderson, has been appointed CEO and president of the company. Anderson has served as the company’s chief operating officer for the past 10 years.
Eliseo Salinas has been named chief research and development officer of Passage Bio. Salinas was recently the chief scientific officer of Acadia Pharmaceuticals.
Sonnet BioTherapeutics has appointed Richard Kenney to the role of chief medical officer and Manuel Dafonseca to head of clinical operations. Kenney was most recently the chief development officer at X-VAX Technology, and Dafonseca was previously Merck’s director of global clinical trial operations for oncology.
Translate Bio has named Rand Sutherland president of the company. Sutherland was recently the global medical head at Sanofi Genzyme.
Ventec Life Systems
Jim Alwan has joined Ventec Life Systems as the company’s new CEO. Alwan was formerly the business leader at Philips.